- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Synonyms :
Class :
patients undergoing anesthesia:
20
mg
Orally
on the night before surgery and 20 mg on the morning of surgery
Initial:
20
mg
Orally
once a day
8
weeks
or longer depending on the improvement of symptoms
20
mg
Orally
once a day
8
weeks
15
mg
Orally
once a day
4
weeks
Maintenance: 15 mg once daily
30
mg
Orally
once a day
8
weeks
30
mg
Orally
3 times a day
with amoxicillin 1000 mg 3 times a day for 14 days
Or
30 mg twice a day with amoxicillin 1000mg and clarithromycin 500 mg twice a day for 10 to 14 days
NSAID-associated gastric ulcer:
Prevention regimen: 15 mg orally once a day for 15 weeks
Treatment: 30 mg orally once a day for 8 weeks
Stress ulcer prophylaxis in critically ill patients:
30 mg orally once a day until the risk factors are resolved
Initial:
20
mg
once a day
The dose can be increased to 20 to 40 mg twice a day if symptoms persist after the initial dose
Children < 11 years (<30kg):
15
mg
Orally
once a day
>30kg: 30 mg orally once a day
Children > 12 years:
30 mg orally once a day
gastro esophageal reflux disease (GERD)
Infants:
1 - 2
mg/kg
Orally
once a day
Children > 12 years and adolescents: 0.7 to 3 mg/kg orally once a day
Or
Infants: 7.5 mg orally twice a day
Children < 11 years:
<30 kg: 15 mg orally once a day
>30 kg: 30 mg orally once a day
Children >12 years: 15 mg orally once a day
when both drugs are combined, there may be a decrease in levels of serum concentration and absorption of erlotinib
it may decrease the serum concentration of belumosudil
may decrease the serum concentration and decrease in the efficacy
rabeprazole increases the effect of fedratinib and vice versa
it may decrease the absorption of Levoketoconazole
they decrease the concentration of active metabolites of infigratinib in the serum
the serum concentration of acalabrutinib may be reduced by Inhibitors of the Proton Pump (PPIs and PCABs)
When bacampicillin is combined with rabeprazole, bacampicillin absorption and blood levels decrease by stomach acid reduction.
when both drugs are combined, there may be an increased risk of hypomagnesemia
it may decrease the serum concentration of Atazanavir
may decrease the therapeutic effect
This could lead to a reduction in concentration serum of mycophenolate